Navigation Links
Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
Date:8/3/2009

BEIJING, Aug. 3 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE AMEX: SVA), a leading provider of vaccines in China, announced today that the clinical trial of its A/H1N1 influenza vaccine is proceeding well. All of the volunteers have received their first shot of the vaccine and, during the three-day observation of safety, the preliminary tests on the A/H1N1 influenza vaccine have indicated that the vaccine is safe and reliable in humans.

The clinical trial began on July 22, 2009 and a total of 1,614 volunteers, including 101 elders, 706 adults, 404 juvenile and 403 children, had received the first shot of the vaccine through July 25. During the three-day safety observation period, none of the volunteers participating in Sinovac's clinical tests exhibited any signs of severe adverse reactions. Total adverse event rate is 11.8%, which is similar to seasonal influenza vaccine. The adverse events were all mild and transient. The most common symptom is pain at the site of injection.

This clinical trial is organized by China's Center for Disease Control (CDC), and undertaken by Beijing CDC. The Ministry of Health (MOH) and State Food and Drug Administration (SFDA) are paying great attention to this clinical trial. Deputy Director General of MOH Disease Control Department, Donglou Xiao, Director of SFDA Registration Section, Wei Zhang, and other relevant experts visited the clinical site to inspect the clinical study. In June 2009, Sinovac announced that the Ministry of Health had made an initial order of 4 million doses of Panflu, which is expected to be delivered by the end of September.

As usual, Sinovac's seasonal influenza vaccine has been released by China SFDA and officially launched to the market at the end of July 2009.

About Sinovac

Sinovac Biotech Ltd. is a China
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sinovac Announces Postponement of Annual General Meeting
2. Sinovac Requests Extension for Annual Shareholders Meeting
3. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
4. Sinovac Closes $9.75 Million Private Placement
5. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
6. Sinovac Announces Adjournment of Annual General Meeting
7. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
8. Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
9. Sinovac Biotech Holds Annual General Meeting
10. Sinovac to Present at the Brean Murray, Carret & Co. All-Cap All-China Conference and the Roth China Discovery Tour 2008
11. Sinovac Receives RMB 20 Million Purchase Order for Healive from Chinas Ministry of Health to Vaccinate Earthquake Victims
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... According to new market research ... Types (Colocation, Enterprise, Telecom), by Design Types (Electrical, ... 2, Tier 3, Tier 4) - Global Forecast ... the Data Center Construction Market into various segments ... This research report also identifies the factors driving ...
(Date:10/25/2014)... 2014 SonaCare Medical, LLC, leader ... technology, announced that its Board of Directors has ... Officer, President and member of the Board effective ... take-on expanded responsibilities within the company, including further ... overseeing commercialization, manufacturing and finance. , Dr. ...
(Date:10/25/2014)... Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" or "RegeneRx") today ... on Thymosins in Health and Disease in ... beta 4 (TB4) linked with rhodamine (a fluorescent tracer ... rodent model of stroke, it was visualized outside of ... tissue of the brain).   The leakage of TB4 in ...
(Date:10/22/2014)... -- Research and Markets has announced ... Market (Product types, Application, Technology, End User and ... Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and ... offering. This new report titled, ... and Geography) Global Size, Industry Analysis, Trends, Opportunities, ...
Breaking Biology Technology:Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3
... recent report that probably went unnoticed outside the academic ... released figures that show why the rest of us ... for scientific research. The numbers demonstrate that investment in ... it's about creating jobs for the 21st century economy. ...
... Technical College would like to see more women going into ... women in IT careers has declined from a high of 41 ... And at MATC, enrollment of women in IT programs has dropped ... IT Expo at the college on Wednesday was Patricia Prime, ...
... . and Imaxio S.A. (Saint-Beauzire, France) have ... manufacture and sell OverExpress bacterial cells for ... retain the right to license the use of OverExpress ... cells to commercial licensees. No license will be required ...
Cached Biology Technology:Tapping hidden assets: Wisconsin researchers who can create jobs 2Tapping hidden assets: Wisconsin researchers who can create jobs 3Tapping hidden assets: Wisconsin researchers who can create jobs 4MATC seeks to turn around falling tech enrollment among women 2Lucigen Corp. enters global licensing agreement 2
(Date:10/15/2014)... , Oct. 15, 2014 Sandata Technologies, ... home and community-based care, today announced it released ... Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™)  for ... a home health company founded in 1996 and ... . The study details the ...
(Date:10/15/2014)... linked increased resistance to bacterial pneumonia in female mice ... estrogen. , Females are naturally more resistant to respiratory ... has shown that increased resistance to bacterial pneumonia in ... synthase 3 (NOS3). They also show that this enzyme ... sex hormone estrogen. , The team, lead by Professor ...
(Date:10/14/2014)... Cancer Research shows SIRT6—a protein known to ... the development of skin cancers by turning on an ... skin cells. , Previously considered protective, SIRT6 is part ... help regulate genomic stability and prevent some of the ... damage, which can lead to cancer. This study, in ...
Breaking Biology News(10 mins):Sandata Announces Case Study with Quality Care Services, Inc. 2Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
... Mass. Joshua Kritzer, assistant professor in the School ... University, has been awarded one of 33 NIH Director,s ... awarded by the National Institutes of Health. The ... to support unusually creative new investigators with highly innovative ...
... -- November 12, 2010 --Canadian biologist Chris Wood was ... Science. The Award was presented by Dr. Philip Campbell, ... for Graduate Studies annual meeting in Toronto earlier this ... Royal Society of Canada, is a professor in the ...
... Powdery mildew is a fungus that infects both crop and ... cause immense crop loss. Despite decades of intense research, little ... to invade the host,s epidermal cells. A European research group ... of Zurich, now published a study in Science ...
Cached Biology News:Tufts University chemist earns prestigious award for promising research on drug development 2Nature honors outstanding faculty mentor 2Fertility or powdery mildew resistance? 2Fertility or powdery mildew resistance? 3
Whole blood is collected from mice (Swiss Webster, 8-10 weeks old,either sex) and processed within 45 minutes of collection. The complement is then filtered and pooled on ice, bottled and stored at -...
... incorporating the sophisticated DirectDrive architecture and ... Varian NMR System is undeniably the ... Varian NMR System features parallel controllers ... providing pulse sequence programming power with ...
... Anti-HMGN2/HMG-17 Immunogen : Recombinant ... pH7.4, 5mg/ml BSA, 0.15M NaCl, ... addition of glycerol to 30% ... immunoblot on acid extracts of ...
Luminometers...
Biology Products: